Antioxidative activity of statins and HDL-PON1 association in lacunar ischemic stroke with and without white matter hyperintensity
1Department of Neurology, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, South Korea
2Department of Neurology, Wonkwang University School of Medicine, Regional Cardiocerebrovascular Center, Iksan, South Korea
3Department of Cardiovascular Medicine, Wonkwang University School of Medicine, Regional Cardiocerebrovascular Center, Iksan, South Korea
Online publish date: 12 January 2021
Purpose: Statins (HMG-coA reductase inhibitors) protect vessels from atherosclerosis through various mechanisms, but the clinical significance of statin-induced high-density lipoprotein cholesterol (HDL) changes has not been established. We evaluated the effects of statin treatment on the antioxidative activities of HDLs in ischemic stroke patients with and without white matter hyperintensity (WMH).
Methods: From January to December in 2013, eighty-two ischemic stroke patients (57 men, 25 women; mean age 67.0 ± 11.8 years) at the Wonkwang Medical Center were recruited retrospectively and antioxidant activity was assessed via paraoxonase 1 (PON1) activity. We studied changes in the patients’ lipid profiles and assessed PON1 activity in patients with and without WMH, at baseline and 8 weeks after treatment with rosuvastatin 10 mg/d.
Results: All patients evaluated antioxidant activity using PON1 activity at admission. After 8 weeks of rosuvastatin treatment, the mean HDL concentration increased to 0.83± 10.1 mg/dL. The HDL levels increased in 54 patients (64.3%) and decreased in 30 patients (35.7%). PON1 activity increased to 15.0% in all patients, regardLess of WMH after rosuvastatin treatment (+ 25.4% in subjects without WMH; P < 0.001). Baseline PON1 activity modestly correlated with HDL levels (r = 0.365, P = 0.019); however, PON1 activity after treatment did not correlate with HDL levels (r = 0.149, P = 0.347).
Conclusion: Our findings suggest that statins increase antioxidant activity, especially assessed via PON1 activity, in ischemic stroke patients who did not have WMH.
Antioxidative effect; Ischemic stroke; Lipid profile; Paraoxonase 1; Statin; White matter hyperintensity
Hyun Goo Kang,Jin Sung Cheong,In Hwan Lim,Kyeong Ho Yun,Hyun Young Park. Antioxidative activity of statins and HDL-PON1 association in lacunar ischemic stroke with and without white matter hyperintensity. Signa Vitae. 2021.doi:10.22514/sv.2021.003.
 Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. The Journal of American Medical Association. 2004; 291: 1071-1080.
 Tan TY, Kuo YL, Lin WC, Chen TY. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis. Journal of Neurology. 2009; 256: 187-193.
 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet. 2005; 366: 1267-1278.
 Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. a possible peroxidative role for paraoxonase. Journal of Clinical Investigation. 1998; 101: 1581-1590.
 Ferré N, Camps J, Fernández-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clinical Chemistry. 2003; 49: 1491-1497.
 Mackness M, Arrol S, Abbott C, Durrington P. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993; 104: 129-135.
 McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clinical Chemistry. 1986; 32: 671-673.
 Brea D, Roquer J, Serena J, Segura T, Castillo J. Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins. BMC Neurology. 2012; 12: 65.
 WardLaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet. Neurology. 2013; 12: 822-838.
 Lavallée PC, Labreuche J, Faille D, Huisse M, Nicaise-Roland P, Dehoux M, et al. Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovascular Diseases. 2013; 36: 131-138.
 Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24: 35-41.
 Hong KS, Yu KH, Rha JH, Kim HY, Koo J, Park JM, et al. Review of evidences and updates of the Korean clinical practice guidelines for stroke in 2013. Journal of the Korean Neurological Association. 2013; 31: 143-157.
 Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. American Journal of Roentgenology. 1987; 149: 351-356.
 Cebeci E, Oner FA, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism. Acta Biomedica de l’Ateneo Parmense. 2011; 82: 214-222.
 Warlow C, SudLow C, Dennis M, WardLaw J, Sandercock P. Stroke. The Lancet. 2003; 362: 1211-1224.
 Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, Ingegni T, et al. Antioxidant profile and early outcome in stroke patients. Stroke. 2000; 31: 2295-2300.
 Arboix A, García-Eroles L, Oliveres M, Targa C, Balcells M, Massons J. Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurology. 2010; 10: 47.
 Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K. Ator-vastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clinical and Experimental Hypertension. 2008; 30: 3-11.
 Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005; 36: 1298-1300.
 Nicholas JS, Swearingen CJ, Thomas JC, Rumboldt Z, Tumminello P, Patel SJ. The effect of statin pretreatment on infarct volume in ischemic stroke. Neuroepidemiology. 2008; 31: 48-56.
 Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radical Biology and Medicine. 2004; 37: 1317-1323.
 Salari N, Rasoulpoor S, Hosseinian-Far A, Razazian N, Mansouri K, Mohammadi M, et al. Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review. Neurological Sciences. 2020.
 Oszukowska M, Kozłowska M, Kaszuba A. Paraoxonase-1 and other factors related to oxidative stress in psoriasis. Postepy Dermatologii I Alergologii. 2020; 37: 92-96.
 de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. Journal of Neurology, Neurosurgery and Psychiatry. 2001; 70: 9-14.
 Blanco-Rojas L, Arboix A, Canovas D, Grau-Olivares M, Oliva Morera JC, Parra O. Cognitive profile in patients with a first-ever lacunar infarct with and without silent lacunes: a comparative study. BMC Neurology. 2013; 13: 203.
 Irace C, Cortese C, Fiaschi E, Scavelli F, Liberatoscioli L, Federici G, et al. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension. Hypertension Research. 2008; 31: 507-513.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.